BlossomHill Therapeutics Presents Preclinical Data On BH-501284 At AACR Conference On Pancreatic Cancer; Targets IND Filing In Q1 2027

BlossomHill Therapeutics presented preclinical data on its KRAS inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer, demonstrating prolonged target engagement and potent antitumor activity in multiple KRAS-mutant cancer models. The company plans to submit an Investigational New Drug (IND) application for BH-501284 in Q1 2027. This novel compound is designed to provide improved efficacy and tolerability compared to existing KRAS-targeted therapies.